Boehringer Ingelheim (Canada) Ltd.
Call for patient/clinician input open:
Call for patient/clinician input closed:
NOC Status at Filing:
Manufacturer Requested Reimbursement Criteria1:
For the treatment of heart failure in patients with New York Heart Association (NYHA) class II, III, or IV. To be used as an adjunct to standard of care therapy.
Jardiance is indicated in adults, as an adjunct to standard of care therapy for the treatment of chronic heart failure.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.